Literature DB >> 28639695

Glycogen synthase kinase-3β ablation limits pancreatitis-induced acinar-to-ductal metaplasia.

Li Ding1, Geou-Yarh Liou2, Daniel M Schmitt3, Peter Storz2, Jin-San Zhang1,4, Daniel D Billadeau1.   

Abstract

Acinar-to-ductal metaplasia (ADM) is a reversible epithelial transdifferentiation process that occurs in the pancreas in response to acute inflammation. ADM can rapidly progress towards pre-malignant pancreatic intraepithelial neoplasia (PanIN) lesions in the presence of mutant KRas and ultimately pancreatic adenocarcinoma (PDAC). In the present work, we elucidate the role and related mechanism of glycogen synthase kinase-3beta (GSK-3β) in ADM development using in vitro 3D cultures and genetically engineered mouse models. We show that GSK-3β promotes TGF-α-induced ADM in 3D cultured primary acinar cells, whereas deletion of GSK-3β attenuates caerulein-induced ADM formation and PanIN progression in KrasG12D transgenic mice. Furthermore, we demonstrate that GSK-3β ablation influences ADM formation and PanIN progression by suppressing oncogenic KRas-driven cell proliferation. Mechanistically, we show that GSK-3β regulates proliferation by increasing the activation of S6 kinase. Taken together, these results indicate that GSK-3β participates in early pancreatitis-induced ADM and thus could be a target for the treatment of chronic pancreatitis and the prevention of PDAC progression.
Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  KRas; S6 K; acinar-to-ductal metaplasia; glycogen synthase kinase-3β; pancreatic cancer; pancreatitis

Mesh:

Substances:

Year:  2017        PMID: 28639695      PMCID: PMC6042855          DOI: 10.1002/path.4928

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  42 in total

Review 1.  GSK-3: tricks of the trade for a multi-tasking kinase.

Authors:  Bradley W Doble; James R Woodgett
Journal:  J Cell Sci       Date:  2003-04-01       Impact factor: 5.285

Review 2.  Pancreatic development and disease.

Authors:  David A Cano; Matthias Hebrok; Martin Zenker
Journal:  Gastroenterology       Date:  2007-02       Impact factor: 22.682

Review 3.  Activator or inhibitor? GSK-3 as a new drug target.

Authors:  Fumi Takahashi-Yanaga
Journal:  Biochem Pharmacol       Date:  2013-05-02       Impact factor: 5.858

4.  Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity.

Authors:  Shiv K Singh; Nai-Ming Chen; Elisabeth Hessmann; Jens Siveke; Marlen Lahmann; Garima Singh; Nadine Voelker; Sophia Vogt; Irene Esposito; Ansgar Schmidt; Cornelia Brendel; Thorsten Stiewe; Jochen Gaedcke; Marco Mernberger; Howard C Crawford; William R Bamlet; Jin-San Zhang; Xiao-Kun Li; Thomas C Smyrk; Daniel D Billadeau; Matthias Hebrok; Albrecht Neesse; Alexander Koenig; Volker Ellenrieder
Journal:  EMBO J       Date:  2015-01-13       Impact factor: 11.598

5.  Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation.

Authors:  K P Hoeflich; J Luo; E A Rubie; M S Tsao; O Jin; J R Woodgett
Journal:  Nature       Date:  2000-07-06       Impact factor: 49.962

6.  Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation.

Authors:  Andrei V Ougolkov; Martin E Fernandez-Zapico; Vladimir N Bilim; Thomas C Smyrk; Suresh T Chari; Daniel D Billadeau
Journal:  Clin Cancer Res       Date:  2006-09-01       Impact factor: 12.531

7.  Glycogen synthase kinase 3-β: a master regulator of toll-like receptor-mediated chronic intestinal inflammation.

Authors:  Claudia Hofmann; Nadja Dunger; Jürgen Schölmerich; Werner Falk; Florian Obermeier
Journal:  Inflamm Bowel Dis       Date:  2010-11       Impact factor: 5.325

8.  GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression.

Authors:  Sandra Baumgart; Nai-Ming Chen; Jin-San Zhang; Daniel D Billadeau; Irina N Gaisina; Alan P Kozikowski; Shiv K Singh; Daniel Fink; Philipp Ströbel; Caroline Klindt; Lizhi Zhang; William R Bamlet; Alexander Koenig; Elisabeth Hessmann; Thomas M Gress; Volker Ellenrieder; Albrecht Neesse
Journal:  Mol Cancer Ther       Date:  2016-01-28       Impact factor: 6.261

Review 9.  Glycogen synthase kinase-3 beta; a new target in pancreatic cancer?

Authors:  G Garcea; M M Manson; C P Neal; C J Pattenden; C D Sutton; A R Dennison; D P Berry
Journal:  Curr Cancer Drug Targets       Date:  2007-05       Impact factor: 3.428

10.  Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-κB and MMPs.

Authors:  Geou-Yarh Liou; Heike Döppler; Brian Necela; Murli Krishna; Howard C Crawford; Massimo Raimondo; Peter Storz
Journal:  J Cell Biol       Date:  2013-08-05       Impact factor: 10.539

View more
  10 in total

1.  Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses.

Authors:  Ilyas Sahin; Aditya Eturi; Andre De Souza; Sahithi Pamarthy; Fabio Tavora; Francis J Giles; Benedito A Carneiro
Journal:  Cancer Biol Ther       Date:  2019-04-12       Impact factor: 4.742

2.  Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response.

Authors:  Li Ding; Vijay S Madamsetty; Spencer Kiers; Olga Alekhina; Andrey Ugolkov; John Dube; Yu Zhang; Jin-San Zhang; Enfeng Wang; Shamit K Dutta; Daniel M Schmitt; Francis J Giles; Alan P Kozikowski; Andrew P Mazar; Debabrata Mukhopadhyay; Daniel D Billadeau
Journal:  Clin Cancer Res       Date:  2019-09-18       Impact factor: 12.531

3.  Nuclear GSK-3β and Oncogenic KRas Lead to the Retention of Pancreatic Ductal Progenitor Cells Phenotypically Similar to Those Seen in IPMN.

Authors:  Li Ding; Kaely Roeck; Cheng Zhang; Brooke Zidek; Esther Rodman; Yasmin Hernandez-Barco; Jin-San Zhang; William Bamlet; Ann Oberg; Lizhi Zhang; Nabeel Bardeesy; Hu Li; Daniel Billadeau
Journal:  Front Cell Dev Biol       Date:  2022-05-13

Review 4.  Glycogen synthase kinase-3β: a novel therapeutic target for pancreatic cancer.

Authors:  Li Ding; Daniel D Billadeau
Journal:  Expert Opin Ther Targets       Date:  2020-03-21       Impact factor: 6.902

5.  Pancreatic triglyceride lipase mediates lipotoxic systemic inflammation.

Authors:  Cristiane de Oliveira; Biswajit Khatua; Pawan Noel; Sergiy Kostenko; Arup Bag; Bijinu Balakrishnan; Krutika S Patel; Andre A Guerra; Melissa N Martinez; Shubham Trivedi; Ann McCullough; Dora M Lam-Himlin; Sarah Navina; Douglas O Faigel; Norio Fukami; Rahul Pannala; Anna Evans Phillips; Georgios I Papachristou; Erin E Kershaw; Mark E Lowe; Vijay P Singh
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

6.  GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.

Authors:  Stephen L Abrams; Shaw M Akula; Akshaya K Meher; Linda S Steelman; Agnieszka Gizak; Przemysław Duda; Dariusz Rakus; Alberto M Martelli; Stefano Ratti; Lucio Cocco; Giuseppe Montalto; Melchiorre Cervello; Peter Ruvolo; Massimo Libra; Luca Falzone; Saverio Candido; James A McCubrey
Journal:  Cells       Date:  2021-04-06       Impact factor: 6.600

7.  An integrated model of acinar to ductal metaplasia-related N7-methyladenosine regulators predicts prognosis and immunotherapy in pancreatic carcinoma based on digital spatial profiling.

Authors:  Hao Yang; Julia Messina-Pacheco; Andrea Liliam Gomez Corredor; Alex Gregorieff; Jun-Li Liu; Ali Nehme; Hamed S Najafabadi; Yasser Riazalhosseini; Bo Gao; Zu-Hua Gao
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

8.  REG3A/REG3B promotes acinar to ductal metaplasia through binding to EXTL3 and activating the RAS-RAF-MEK-ERK signaling pathway.

Authors:  Huairong Zhang; Andrea Liliam Gomez Corredor; Julia Messina-Pacheco; Qing Li; George Zogopoulos; Nancy Kaddour; Yifan Wang; Bing-Yin Shi; Alex Gregorieff; Jun-Li Liu; Zu-Hua Gao
Journal:  Commun Biol       Date:  2021-06-07

9.  9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer.

Authors:  Hiroo Kuroki; Tsutomu Anraku; Akira Kazama; Vladimir Bilim; Masayuki Tasaki; Daniel Schmitt; Andrew P Mazar; Francis J Giles; Andrey Ugolkov; Yoshihiko Tomita
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

10.  9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells.

Authors:  Andrey Poloznikov; Sergey Nikulin; Larisa Bolotina; Andrei Kachmazov; Maria Raigorodskaya; Anna Kudryavtseva; Ildar Bakhtogarimov; Sergey Rodin; Irina Gaisina; Maxim Topchiy; Andrey Asachenko; Victor Novosad; Alexander Tonevitsky; Boris Alekseev
Journal:  Front Pharmacol       Date:  2021-12-09       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.